New water-soluble sulfonylphosphoramidic acid derivatives of the COX-2 selective inhibitor cimicoxib. A novel approach to sulfonamide prodrugs

Journal of Medicinal Chemistry

Volumn 47, Issue 22, 2004, Pages 5579-5582

  Almansa, Carmen ^a   Bartrolí, Javier ^a   Belloc, Jordi ^a   Cavalcanti, Fernando L ^a   Ferrando, Rosa ^a   Gómez, Luis A ^a   Ramis, Isabel ^a   Carceller, Elena ^a   Merlos, Manuel ^a   García Rafanell, Julián ^a  

^a Grupo Uriach   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARRAGEENAN; CIMICOXIB; CYCLOOXYGENASE 2 INHIBITOR; MORPHINE; N [4 [4 CHLORO 5 (3 FLUORO 4 METHOXYPHENYL)IMIDAZOLE 1 YL]PHENYLSULFONYL]PHOSPHORAMIDIC ACID; PHOSPHORAMIDIC ACID DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG; UR 14048;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SOLUBILITY; DRUG SYNTHESIS; HYPERALGESIA; MALE; NONHUMAN; PAW EDEMA; RAT; STRUCTURE ACTIVITY RELATION; THERMAL STIMULATION;

ACUTE DISEASE; AMIDES; ANIMALS; CARRAGEENAN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOGS; EDEMA; HALF-LIFE; HUMANS; HYPERALGESIA; IMIDAZOLES; ISOENZYMES; MALE; MEMBRANE PROTEINS; PAIN MEASUREMENT; PHOSPHORIC ACIDS; PRODRUGS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, WISTAR; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; WATER;

EID: 6044234751     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040844j     Document Type: Article

References (30)

1. Lewis, K. S.; Whipple, J. K.; Michael, K. A.; Quebbeman, E. J. Effect of Analgesic Treatment on the Physiological Consequences of Acute Pain. Am. J. Hosp. Pharm. 1994, 51, 1539-1554.
2. Strom, B. L.; Berlin, J. A.; Kinman, J. L.; Spitz, P. W.; Hennessy, S.; Heldman, H.; Kimmel, S.; Carson, J. L. Parenteral Ketorolac and Risk of Gastrointestinal and Operative Site Bleeding: A Post-marketing Surveillance Study. J. Am. Med. Assoc. 1996, 275, 376-382.
3. (a) Xie, W.; Chipman, J. G.; Robertson, D. L.; Erikson, R. L.; Simmons, D. L. Expression of a Mitogen-responsive Gene Encoding Prostaglandin Synthase is Regulated by mRNA Splicing. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2692-2696.
4. (b) Jujubu, D. A.; Fletcher, B. S.; Varnum, B. C.; Lim, R. W.; Herschman, H. R. TIS10, a Phorbol Ester Tumor Promoter-Inducible mRNA from Swiss 3T3 Cells, Encodes a Novel Prostaglandin Synthase/Cyclooxygenase Homologue. J. Biol. Chem. 1991, 266, 12866-12872.
5. (c) Vane, J. R. Towards a Better Aspirin. Nature 1994, 367, 215-16.
6. (d) Masferrer, J. L.; Zweifel, B. S.; Manning, P. T. Selective Inhibition of Inducible Cyclooxygenase-2 in vivo is Antiinflammatory and Nonulcerogenic. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3228-3232.
7. (a) Kalgutkar, A. S. Selective Cyclooxygenase-2 Inhibitors as Nonulcerogenic Antiinflammatory Agents. Exp. Opin. Ther. Patents 1999, 9, 831-849.
8. (b) Reitz, D. B.; Isakson, P. C. Cyclooxygenase-2 Inhibitors. Current Pharm. Design 1995, 1, 211-220.
9. (c) Carter, J. S. Recently Reported Inhibitors of Cyclooxygenase-2. Exp. Opin. Ther. Patents 1997, 8, 21-29.
10. Prasit, P.; Wang, Z.; Brideau, C.; Chan, C.-C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Léger, S.; Mancini, J.; O'Neill, G. P.; Ouellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, Y.; Tagari, P.; Thérien, M.; Vickers, P.; Wong, E.; Xu, L.-J.; Young, R. N.; Zamboni, R. The Discovery of Rofecoxib, [MK 966, Vioxx, 4-(4′-Methylsulfonylphenyl)-3-phenyl-2(5H)furanone], an Orally Active Cyclooxygenase-2 Inhibitor. Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778.
11. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
12. Talley, J. J.; Brown, D. L.; Carter, J. S.; Graneto, M. J.; Koboldt, C. M.; Masferrer, J. L.; Perkins, W. E.; Rogers, R. S.; Shaffer, A. F.; Zhang, Y. Y.; Zweifel, B. S.; Seibert, K. 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2. J. Med. Chem. 2000, 43, 775-777.
13. Riendeau, D.; Percival, M. D.; Brideau, C.; Charleson, S.; Dubé, D.; Ethier, D.; Falgueyret, J. P.; Friesen, R. W.; Gordon, R.; Greig, G.; Guay, J.; Mancini, J.; Oellet, M.; Wong, E.; Xu, L.; Boyce, S.; Visco, D.; Girard, Y.; Prasit, P.; Zamboni, R.; Rodger, I. W.; Gresser, M.; Ford-Hutchinson, A. W.; Young, R. N.; Can, C. C. Etoricoxib (MK-0663): Preclinical Profile and Comparison with other Agents that Selectively Inhibit Cyclooxygenase-2. J. Pharmacol. Exp. Ther. 2001, 296, 558-566.
14. Talley, J. J.; Bertershaw, S. R.; Brown, D. L.; Carter, J. S.; Graneto, M. J.; Kellogg, M. S.; Koboldt, C. M.; Yuan, J.; Zhang, Y. Y.; Seibert, K. N-[[(5-Methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, Sodium Salt, Parecoxib Sodium: A Potent and Selective Inhibitor of COX-2 for Parenteral Administration. J. Med. Chem. 2000, 43, 1661-1663.
15. Almansa, C.; Alfon, J.; de Arriba, A. F.; Cavalcanti, F.; Escamilla, I.; Gómez, L.; Miralles, A.; Bartroli, J.; Carceller, E.; Merlos, M.; García-Rafanell, J. Synthesis and Structure-activity Relationship of a new Series of COX-2 Selective Inhibitors: 1,5-Diarylimidazoles. J. Med. Chem. 2003, 46 (3), 3463-3475.
16. Larsen, J. D.; Bundgaard, H. Prodrug Forms for the Sulfonamide Group. I Evaluation of N-Acyl Derivatives, N-Sulfonylamidines, N-Sulfonylsulfilimines and Sulfonylureas as Possible Prodrug Derivatives. Int. J. Pharm. 1987, 37, 87-95.
17. Bundgaard, H.; Larsen, J. D. N-Sulfonyl Imidates as a Novel Prodrug Form for an Ester Function of a Sulfonamide Group. J. Med. Chem. 1988, 31, 2066-2069.
18. Johnson, D. C.; Widlanski, T. S. Facile Synthesis of 5′-(N-acyl Sulfonamide) Derivatized Nucleosides. Tetrahedron Lett. 2001, 3677-3679.
19. MacKay, W. R.; Proctor, G. R. Removal of Toluene-p-Sulphonyl Groups from Sulphonamides. Part 4. Synthesis of Phenylglyoxal Imine Monomers. J. Chem. Soc., Perkin Trans. 1981, 31, 2435-2442.
20. Lukanov, L.; Venkov, A.; Mollov, N. The Application of Phase-Transfer Catalyzed Version of Atherton-Todd Reaction to Sulfonamides. Synth. Commun. 1986, 16, 767-773.
21. Rätz, R. Diethyl N-Arylsulfonylphosphoramidates. J. Org. Chem. 1957, 22, 372-374.
22. Goldstein, J. A. N-Alkyl (Aryl) Sulfonylphosphoramidate Monoesters. J. Org. Chem. 1977, 42, 2466-2469.
23. (a) Fenesan, I.; Popescu, R.; Scozzafava, A.; Crudin, V.; Mateiciuc, E.; Bauer, R.; Ilies, M. A.; Supuran, C. T. Carbonic anhydrase Inhibitors; Phosphoryl-Sulfonamides - A New Class of High Affinity Inhibitors of Isozymes I and II. J. Enzymol. Inhibition. 2000, 15, 297-310.
24. (b) Zhu, S.; Xu, G.; Qin, C.; Xu, Y.; Chu, Q. Synthesis of Diethyl N(Perfluoroalkanesulfonyl)phosphoramidates and N-(Perfluoroalkanesulfonyl) phosphoramidic acids. Phosphorous, Sulfur Silicon Relat. Elem. 1998, 140, 53-61.
25. (c) Haubold, W.; Becke-Goehring M. Phosphorous Nitrogen Compounds XXIII. Hydrolysis of Compounds Which Contain Trichlorophosphazo Group. Z. Anorg. Allg. Chem. 1967, 352, 113-121.
26. (d) Ishimaru, T.; Kodama, Y. German Patent Document DE 2344130, 1974.
27. Murdock, K. C.; Lee, V. L.; Citarella, R. V.; Durr, F. E.; Nicolau, G.; Kohlbrenner, M. N-Phosphoryl Derivatives of Bisantrene. Antitumor Prodrugs with Enhanced Solubility and Reduced Potential for Toxicity. J. Med. Chem. 1993, 36, 2098-2101.
28. Hargreaves, K.; Dubner, R.; Brown, F.; Flores, C.; Joris, J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32, 77-88.
29. Ionization constants were measured by potentiometric titration in 0.15 M KCl at 25 °C using a PCA200 instrument (Sirius Analytical Instruments).
30. Equilibrium solubilities were obtained by adding solid compounds directly to an aqueous medium, followed by stirring at room temperature for 16 h. Suspensions were then filtered and the remaining concentration in the solution was measured by HPLC.